Promega to further develop OncoMate MSI assay

2020 07 20 15 52 6356 Epidemiologist Lab 400

Promega announced that it plans to further develop its OncoMate microsatellite instability (MSI) assay as a companion diagnostic test for Incyte's anti-PD-1 drug candidate for endometrial cancer, retifanlimab.

MSI-high (MSI-H) occurs often in endometrial cancer, Promega said; MSI-H tumors respond well to PD-1 inhibitor treatment.

OncoMate MSI Assay received the CE Mark in Europe earlier in the year. Promega and Incyte plan to collaborate on developing OncoMate MSI Assay as a companion diagnostic in other markets as well.

Page 1 of 10
Next Page